A 24-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Effect of LCZ696 on NT-proBNP, Symptoms, Exercise Function and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction

Trial Profile

A 24-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Effect of LCZ696 on NT-proBNP, Symptoms, Exercise Function and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Enalapril; Valsartan
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms PARALLAX
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 29 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 30 Jun 2017 Planned initiation date changed from 15 Jun 2017 to 8 Sep 2017.
    • 02 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top